HRP20230612T1 - Formulacije kopanlisiba - Google Patents
Formulacije kopanlisiba Download PDFInfo
- Publication number
- HRP20230612T1 HRP20230612T1 HRP20230612TT HRP20230612T HRP20230612T1 HR P20230612 T1 HRP20230612 T1 HR P20230612T1 HR P20230612T T HRP20230612T T HR P20230612TT HR P20230612 T HRP20230612 T HR P20230612T HR P20230612 T1 HRP20230612 T1 HR P20230612T1
- Authority
- HR
- Croatia
- Prior art keywords
- copanlisib
- solid containing
- lyophilized solid
- amount
- containing copanlisib
- Prior art date
Links
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 title claims 34
- 229950002550 copanlisib Drugs 0.000 title claims 34
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007787 solid Substances 0.000 claims 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 16
- 239000011780 sodium chloride Substances 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 238000011287 therapeutic dose Methods 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000008227 sterile water for injection Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Luminescent Compositions (AREA)
- Road Signs Or Road Markings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Stabilna, liofilizirana krutina koja sadrži kopanlisib, pogodna za razrjeđivanje i za terapeutske primjene, te navedena krutina sadrži:
• kopanlisib, naročito u količini prikladnoj kao terapijska doza,
• jedno ili više sredstava za podešavanje pH, što je sredstvo za puferiranje koje se sastoji od slabe kiseline, kao što je na primjer limunska kiselina, i jake baze, kao što je na primjer natrijev hidroksid, i
• sredstvo za povećanje volumena, pri čemu je navedeno sredstvo za povećanje volumena manitol,
navedena krutina ima pH između 4 i 5 (uključivo) kada se rekonstituira s prikladnim razrjeđivačem, kao što je sterilna voda za injekcije ili sterilna vodena otopina natrijevog klorida, naročito na primjer 0.9% vodena otopina natrijevog klorida, navedena terapijska doza je 30, 45 ili 60 mg kopanlisiba.
2. Liofilizirana krutina koja sadrži kopanlisib prema zahtjevu 1, naznačena time što je navedeno pufersko sredstvo limunska kiselina i natrijev hidroksid.
3. Liofilizirana krutina koja sadrži kopanlisib prema zahtjevu 1 ili 2, koja sadrži limunsku kiselinu u količini od 0,7-75% m/m, naročito 1,5-30% m/m, naročito 2,98% m/m, navedene liofilizirane krutine koja sadrži kopanlisib.
4. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 3, koja sadrži natrijev hidroksid u količini od 0-6% m/m, naročito 3,3-4,0% m/m, naročito 3,7% m/m, navedene liofilizirane krutine koja sadrži kopanlisib.
5. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 4, koja sadrži natrijev hidroksid u količini od 0,01-6% m/m, naročito 3,3-4,0% m/m, naročito 3,7% m/m, navedene liofilizirane krutine koja sadrži kopanlisib.
6. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 5, koja sadrži manitol u količini od 15,4-82,1% m/m, naročito 30,8-82,1% m/m, naročito 61,6% m/m, navedene liofilizirane krutine koja sadrži kopanlisib.
7. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 6, koja sadrži navedenu slobodnu bazu kopanlisiba u količini od 7,7-92,4% m/m, naročito 7,7-61,6% m/m, naročito 30,8% m/m, liofilizirane krutine koja sadrži kopanlisib.
8. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 7, naznačena time što:
• navedena terapijska doza kopanlisiba je u količini od 30,8% m/m navedene liofilizirane krutine koja sadrži kopanlisib,
• navedena limunska kiselina je u količini od 2,98% m/m navedene liofilizirane krutine koja sadrži kopanlisib,
• navedeni natrijev hidroksid je u količini od 3,7% m/m navedene liofilizirane krutine koja sadrži kopanlisib, i
navedeni manitol je u količini od 61,6% m/m, navedene liofilizirane krutine koja sadrži kopanlisib,
navedena liofilizirana krutina koja sadrži kopanlisib, kada se rekonstituira s prikladnim razrjeđivačem, kao što je sterilna voda za injekcije ili sterilna vodena otopina natrijevog klorida, na primjer naročito 0,9% vodena otopina natrijevog klorida, ima pH između 4 i 5 (uključivo).
9. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 8, naznačena time što:
• navedena terapijska doza kopanlisiba je u količini od 30, 45 ili 60 mg,
• navedena limunska kiselina je u količini od 5,8 mg,
• navedeni natrijev hidroksid je u količini od 6,3 mg, i
• navedeni manitol je u količini od 120 mg,
navedena liofilizirana krutina koja sadrži kopanlisib, kada se rekonstituira s prikladnim razrjeđivačem, kao što je sterilna voda za injekcije ili sterilna vodena otopina natrijevog klorida, naročito na primjer 0,9% vodena otopina natrijevog klorida, ima pH između 4 i 5 (uključivo).
10. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 9, naznačena time što:
• navedena terapijska doza kopanlisiba je u količini od 80 mg,
• navedena limunska kiselina je u količini od 7,7 mg,
• navedeni natrijev hidroksid je u količini od 8,4 mg, i
• navedeni manitol je u količini od 160 mg,
navedena liofilizirana krutina koja sadrži kopanlisib, kada se rekonstituira s prikladnim razrjeđivačem, kao što je sterilna voda za injekcije ili sterilna vodena otopina natrijevog klorida, naročito na primjer 0,9% vodena otopina natrijevog klorida, ima pH između 4 i 5 (uključivo).
11. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 10, naznačena time što je prah ili kolač.
12. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 11, naznačena time što je sadržana u jednom spremniku, naročito zatvorenom spremniku, naročito bočici za injekciju, točnije bočici za injekciju od 6 ml.
13. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 12, naznačena time što sadrži kopanlisib u količini od 68,4 mg.
14. Liofilizirana krutina koja sadrži kopanlisib prema bilo kojem od zahtjeva 1 do 13,
za upotrebu u liječenju ili profilaksi raka, naročito ne-Hodgkinovog limfoma (NHL), kao što je 1. linija, 2. linija ili do 9 prethodnih tretmana, relapsirajućeg, refraktornog, indolentnog NHL, naročito folikularnog limfoma (FL), limfoma rubne zone (MZL), malog limfocitnog limfoma (SLL), limfoplazmocitoidne/Waldenströmove makroglobulinemije (LPL-WM), ili agresivnog NHL, naročito difuznog limfoma velikih B stanica (DLBCL), limfoma stanica plašta (MCL), perifernog T-staničnog limfoma (PTCL), transformiranog limfoma (TL), ili kronične limfocitne leukemije (CLL), kao monoterapija ili u kombinaciji s jednim ili više imunoterapijskih, kemoterapijskih ili imuno-kemoterapijskih sredstava protiv raka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17190117 | 2017-09-08 | ||
| EP17207771.1A EP3498266A1 (en) | 2017-12-15 | 2017-12-15 | Formulations of copanlisib |
| PCT/EP2018/073965 WO2019048527A1 (en) | 2017-09-08 | 2018-09-06 | COPANLISIB FORMULATIONS |
| EP18762107.3A EP3678644B1 (en) | 2017-09-08 | 2018-09-06 | Formulations of copanlisib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230612T1 true HRP20230612T1 (hr) | 2023-09-29 |
Family
ID=63407234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230612TT HRP20230612T1 (hr) | 2017-09-08 | 2018-09-06 | Formulacije kopanlisiba |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20200281932A1 (hr) |
| EP (1) | EP3678644B1 (hr) |
| JP (2) | JP2020533292A (hr) |
| KR (1) | KR20200052326A (hr) |
| CN (1) | CN111278430A (hr) |
| AU (1) | AU2018328812A1 (hr) |
| BR (1) | BR112020004545A2 (hr) |
| CA (1) | CA3074890A1 (hr) |
| CL (1) | CL2020000584A1 (hr) |
| CO (1) | CO2020002628A2 (hr) |
| CR (1) | CR20200111A (hr) |
| CU (1) | CU24607B1 (hr) |
| DK (1) | DK3678644T3 (hr) |
| DO (1) | DOP2020000054A (hr) |
| ES (1) | ES2950663T3 (hr) |
| FI (1) | FI3678644T3 (hr) |
| GE (1) | GEP20237486B (hr) |
| HR (1) | HRP20230612T1 (hr) |
| HU (1) | HUE063178T2 (hr) |
| IL (1) | IL272857B2 (hr) |
| JO (1) | JOP20200053A1 (hr) |
| LT (1) | LT3678644T (hr) |
| MA (1) | MA50068A (hr) |
| MX (1) | MX2020002633A (hr) |
| NI (1) | NI202000019A (hr) |
| PH (1) | PH12020500448A1 (hr) |
| PL (1) | PL3678644T3 (hr) |
| RS (1) | RS64316B1 (hr) |
| SG (1) | SG11202001696QA (hr) |
| SI (1) | SI3678644T1 (hr) |
| TW (1) | TWI794288B (hr) |
| UA (1) | UA126817C2 (hr) |
| UY (1) | UY37868A (hr) |
| WO (1) | WO2019048527A1 (hr) |
| ZA (1) | ZA202002378B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4070785B1 (en) | 2021-04-06 | 2023-11-08 | Synthon B.V. | Lyophilized composition of copanlisib salt |
| CN115252613B (zh) * | 2022-08-09 | 2024-01-12 | 北京清华长庚医院 | 药物组合物及其在逆转仑伐替尼耐药性中的用途 |
| WO2024069239A1 (en) * | 2022-09-28 | 2024-04-04 | Urogen Pharma Ltd. | Compositions comprising a thermoreversible hydrogel, and having an extended in-use period |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ539062A (en) | 2002-09-30 | 2007-05-31 | Bayer Pharmaceuticals Corp | Fused azole-pyrimidine derivatives exhibiting enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA3012951A1 (en) * | 2016-02-01 | 2017-08-10 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
| WO2017134000A1 (en) * | 2016-02-01 | 2017-08-10 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
-
2018
- 2018-09-06 PL PL18762107.3T patent/PL3678644T3/pl unknown
- 2018-09-06 SG SG11202001696QA patent/SG11202001696QA/en unknown
- 2018-09-06 CA CA3074890A patent/CA3074890A1/en active Pending
- 2018-09-06 IL IL272857A patent/IL272857B2/en unknown
- 2018-09-06 ES ES18762107T patent/ES2950663T3/es active Active
- 2018-09-06 JP JP2020513544A patent/JP2020533292A/ja active Pending
- 2018-09-06 KR KR1020207009732A patent/KR20200052326A/ko active Search and Examination
- 2018-09-06 MX MX2020002633A patent/MX2020002633A/es unknown
- 2018-09-06 DK DK18762107.3T patent/DK3678644T3/da active
- 2018-09-06 GE GEAP201815306A patent/GEP20237486B/en unknown
- 2018-09-06 CU CU2020000017A patent/CU24607B1/es unknown
- 2018-09-06 EP EP18762107.3A patent/EP3678644B1/en active Active
- 2018-09-06 TW TW107131361A patent/TWI794288B/zh active
- 2018-09-06 HU HUE18762107A patent/HUE063178T2/hu unknown
- 2018-09-06 LT LTEPPCT/EP2018/073965T patent/LT3678644T/lt unknown
- 2018-09-06 UA UAA202002130A patent/UA126817C2/uk unknown
- 2018-09-06 HR HRP20230612TT patent/HRP20230612T1/hr unknown
- 2018-09-06 CR CR20200111A patent/CR20200111A/es unknown
- 2018-09-06 FI FIEP18762107.3T patent/FI3678644T3/fi active
- 2018-09-06 SI SI201830943T patent/SI3678644T1/sl unknown
- 2018-09-06 BR BR112020004545-4A patent/BR112020004545A2/pt not_active Application Discontinuation
- 2018-09-06 CN CN201880072307.9A patent/CN111278430A/zh active Pending
- 2018-09-06 JO JOP/2020/0053A patent/JOP20200053A1/ar unknown
- 2018-09-06 MA MA050068A patent/MA50068A/fr unknown
- 2018-09-06 RS RS20230535A patent/RS64316B1/sr unknown
- 2018-09-06 US US16/644,472 patent/US20200281932A1/en not_active Abandoned
- 2018-09-06 AU AU2018328812A patent/AU2018328812A1/en active Pending
- 2018-09-06 WO PCT/EP2018/073965 patent/WO2019048527A1/en unknown
- 2018-09-07 UY UY0001037868A patent/UY37868A/es not_active Application Discontinuation
-
2020
- 2020-03-05 PH PH12020500448A patent/PH12020500448A1/en unknown
- 2020-03-06 CL CL2020000584A patent/CL2020000584A1/es unknown
- 2020-03-06 DO DO2020000054A patent/DOP2020000054A/es unknown
- 2020-03-06 NI NI202000019A patent/NI202000019A/es unknown
- 2020-03-09 CO CONC2020/0002628A patent/CO2020002628A2/es unknown
- 2020-05-04 ZA ZA2020/02378A patent/ZA202002378B/en unknown
-
2023
- 2023-03-07 JP JP2023034647A patent/JP2023071917A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230612T1 (hr) | Formulacije kopanlisiba | |
| HRP20200777T1 (hr) | Formulacije koje sadrže triazinone i željezo | |
| HRP20211813T1 (hr) | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MY188749A (en) | Compositions comprising a combination of nivolumab and ipilimumab | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
| EA201792224A1 (ru) | Композиции, содержащие ибрутиниб | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| MX2021002998A (es) | Compuestos de triazolo-pirimidina y usos de los mismos. | |
| MX2018015094A (es) | Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos. | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| MX2007014082A (es) | Pirido[2,3-d]pirimidinas utiles como inhibidores del virus de la hepatitis c (hcv), y metodos para la preparacion de las mismas. | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| PH12017500159B1 (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
| MY194702A (en) | Liquid skin cleansing agent composition | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| WO2012168885A3 (en) | Bisacodyl and its analogues as drugs for use in the treatment of cancer | |
| PH12019500808A1 (en) | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | |
| MX2020004981A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| RU2013110517A (ru) | Средство для профилактики или лечения неалкогольного стеатогепатита | |
| MX2015012716A (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. | |
| BR112018012307A2 (pt) | derivados de pirrol[3,2-c]piridina-6-amino | |
| BR112015017628A2 (pt) | uso de compostos de fenoxipropilamina para tratar a depressão |